Connect with us

Press Release

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Published

on

SHENZHEN, CHINA China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.

 

The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the Chinas National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.

 

The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.

 

More information about Monofer®

Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.

 

More information about Cosmofer®

Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.

 

About Iron Deficiency and Iron Deficiency Anemia

ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.

 

About Pharmacosmos A/S

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

  1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
  2. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
  3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
  5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
  6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

From a Calling to International Recognition: ENKU Brings Japanese Calligraphy to Global Audiences

Published

on

Japan, 19th Jun 2026 — Self-taught Japanese calligraphy artist ENKU is developing a contemporary body of work that combines traditional calligraphy, performance, installation art, and cultural storytelling.

Beginning his calligraphy journey in 2024 without formal training, ENKU draws inspiration from language, Japanese cultural traditions, history, and the relationship between written characters and human experience.

Through exhibitions, live performances, and collaborative projects, ENKU explores how calligraphy can be experienced not only as writing, but also as visual art, movement, sound, light, and reflection.

Latest Publicly Released Work

Picture 1

Exhibited in Shibuya, Tokyo, in November 2025, ENKU’s latest publicly presented work explores themes of meaning, purpose, reflection, focus, direction, and character through a composition inspired by traditional Japanese and Buddhist visual concepts. The work is structured around two symbolic worlds: one connected to spirit, wisdom, and clarity, and the other connected to life, light, and origin.

The composition brings together four interconnected concepts related to purpose, focus, direction, and character. Created using gold and silver foil, the appearance of the work changes depending on the viewer’s position and angle. ENKU created the piece with the intention of encouraging reflection, calm, and contemplation.

Koto and Calligraphy Collaboration Performance

Picture 2

In June 2025, ENKU presented a collaborative performance combining Japanese koto and live calligraphy. For the performance, he created a custom gold folding screen and incorporated two central themes: the miracle of life and the flow of time.

Using glow-in-the-dark materials, ENKU transformed the performance space into an immersive visual experience, expressing these ideas through lines and points of light emerging from darkness. The work invited audiences to experience changing perspectives through the folding screen structure, light, and movement.

The Story Behind the Artist

ENKU traces the beginning of his calligraphy journey to a deeply personal experience in late 2023, which inspired him to begin studying calligraphy independently in March 2024 despite having no formal training or prior experience beyond elementary school handwriting classes.

Originally drawn to language, Japanese culture, tradition, and history, ENKU’s work explores the origins and meanings of words, the beauty of written forms, and the cultural idea that words can carry influence beyond their literal definitions.

From First Exhibition Challenge to Ongoing Practice

Shortly after beginning calligraphy, ENKU decided to pursue international opportunities and applied for a New York exhibition after discovering an open call through social media. Once accepted, he faced the challenge of creating an exhibition-ready artwork despite never having made one before.

As the deadline approached, he struggled to create a work he felt satisfied with. A single phrase, translated as “Divine Wind,” came to mind, and the piece inspired by that phrase became his first exhibited work. ENKU describes this as his first major wall as an artist.

Why Calligraphy Matters in the Age of AI

ENKU believes contemporary calligraphy offers a physical, time-intensive, and human experience in an increasingly digital age. He sees the act of creating and encountering calligraphy as something that can refine people’s sensibilities and give viewers a direct experience of being alive.

At a time when AI is becoming increasingly present, ENKU’s work emphasizes hand-made expression, material presence, physical effort, and the emotional impact of written form.

Future Vision

Through calligraphy, ENKU aims to become an artist active not only in Japan but around the world. One of his long-term goals is to create a work valued at 100 million yen.

Japanese Taiko Drums, Koto, and Calligraphy Collaboration Performance

Picture 3

In November 2024, ENKU presented an early collaborative performance combining Japanese taiko drums, koto, and calligraphy. The performance explored the relationship between sound, language, meaning, and written expression through layered calligraphic forms.

This performance marked one of ENKU’s first attempts to expand calligraphy beyond the page and into a live, multi-sensory format.

About ENKU

ENKU is a self-taught Japanese calligraphy artist based in Tokyo. Beginning his calligraphy practice in 2024, he combines traditional Japanese calligraphy with contemporary performance, installation, light-based expression, and themes rooted in language, culture, history, and human experience.

Media Contact: 

ENKU | Contemporary Calligraphy Artist

Email: enku.u.sky@gmail.com

Phone: +81 80 4189 3903

Instagram: https://www.instagram.com/enku.u_do01 

LinkedIn: https://www.linkedin.com/in/enku11011  

Media Contact

Organization: Contemporary calligraphy artist ENKU

Contact Person: ENKU

Website: https://www.linkedin.com/in/enku11011

Email: Send Email

Country:Japan

Release id:46259

The post From a Calling to International Recognition: ENKU Brings Japanese Calligraphy to Global Audiences appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

First Hyperliquid Holders Secure Assets Against the Quantum Threat as qVAULT Launches

Published

on

qLABS launches qVAULT, secured with Falcon post-quantum cryptography, bringing quantum-resistant protection to institutional and DeFi digital asset holders.

Panama, 19th Jun 2026 – qLABS, a quantum-native Web3 foundation, today launched qVAULT, the first quantum-safe vault for digital assets for everyone. qVAULT is the first live product to let Hyperliquid holders keep HYPE, Hyperliquid’s native digital asset, in post-quantum self-custody, and the launch puts post-quantum protection, long confined to research papers and conference slides, into a product holders run themselves. The first HYPE on HyperEVM has already moved into qVAULT post-quantum vaults during early access.

qVAULT is a post-quantum, self-custody smart-contract vault for crypto that lets holders move assets out of elliptic-curve-only control and into vaults that sign with Falcon (FN-DSA), the signature scheme the U.S. National Institute of Standards and Technology (NIST) selected for standardization.

The quantum threat is concrete and present. The major public chains, including Bitcoin, Ethereum, and Hyperliquid through HyperEVM, secure funds with elliptic-curve signatures. HyperEVM authenticates with ECDSA over the secp256k1 curve, the same scheme Ethereum uses. A sufficiently capable quantum computer will break that cryptography and expose any address whose public key has appeared on chain. Because a public key revealed on chain today can be harvested and broken once that hardware exists, “harvest now, decrypt later” makes this a liability holders carry today, not a problem for a later decade.

qVAULT quantum-safe smart contract vault signs with Falcon (FN-DSA), the scheme NIST selected for standardization and currently in public review as FIPS 206. Since qVAULT is a non-custodial solution, qLABS never holds keys or seed phrases. The path into the vault has three steps: connect a self-custody account such as MetaMask, create a Falcon-secured vault, and bring assets across, out of ECDSA-only control and under a post-quantum signature.

qLABS is not making the case alone. A growing group of institutional and DeFi participants is working with the foundation on what post-quantum security means for their corner of the market. Two of them are public companies: HYLQ Strategy Corp (CSE: HYLQ), the first corporate treasury to hold HYPE, is evaluating quantum-safe custody for its position, and DigitalX (ASX: DCC), an institutional digital asset manager, recently took part in a quantum-preparedness workshop run by qLABS and 01 Quantum. On the DeFi side, the bonding protocol ApeBond is assessing post-quantum protection for its markets.

qVAULT’s design and threat model are public in a published litepaper, and its code has passed an independent security audit by Fairyproof. The cryptography itself is overseen by people who help set the standard: qLABS’ advisory board includes Dr. Edoardo Persichetti, co-author of HQC, an algorithm NIST selected for post-quantum standardization, and Aaron Moore, former CTO of QuSecure with a background at the NSA and DARPA.

Hyperliquid has become the center of gravity for on-chain trading: more than 3.5 trillion USD in cumulative volume, over 9 billion USD in open interest, and roughly 70 percent of open interest across all on-chain perpetuals exchanges, more than every competitor combined. Yet while Ethereum, Solana, and BNB Chain have all published quantum-resistance roadmaps, research, or live test results, Hyperliquid has not yet published a comparable plan. Until it does, protection in its ecosystem sits exactly where qVAULT puts it: in the hands of the holder. qONE, the qLABS native token powering qVAULT, has traded on Hyperliquid since February 2026.

“For years, post-quantum security lived in standards drafts and conference talks, with nowhere to put real money,” said Andrew Cheung, CTO of qLABS and President and CEO of 01 Quantum Inc. (TSXV: ONE; OTCQB: OONEF), a strategic partner of qLABS. “qVAULT closes that gap: a place holders move real assets onto Falcon signatures today, keep their own keys, and do it inside a live, audited smart-contract environment. That combination turns harvest-now-decrypt-later from a warning into something you can act on before the Q-Day arrives.”

“Hyperliquid is the best thing to happen to finance in years, real markets, real size, fully on-chain,” said Antanas Guoga (Tony G), President of qLABS. “The institutions and protocols that move first on post-quantum security are the ones prepared when the threat stops being theoretical. Protecting the best of on-chain finance is exactly where that starts.”

 

About qVAULT

qVAULT is a post-quantum, self-custody smart-contract vault for crypto. It signs with Falcon (FN-DSA), the signature scheme NIST selected for standardization and currently in public review as FIPS 206, letting holders move assets out of ECDSA-only control while retaining full custody. qLABS never holds keys or seed phrases.

Learn more: qvault.xyz 

About qLABS

qLABS is a quantum-native Web3 foundation building post-quantum security for digital assets, with qVAULT as its flagship product and qONE as its native token. Its advisory board includes Dr. Edoardo Persichetti, co-author of the NIST-selected HQC algorithm, and Aaron Moore, former CTO of QuSecure. 01 Quantum Inc. (TSXV: ONE; OTCQB: OONEF) is a strategic technological partner of qLABS.

For more details contact: gintautas@qlabs.tech
 

Media Contact

Organization: qLABS

Contact Person: Ada Jonuse

Website: https://qlabs.tech/

Email: Send Email

Country:Panama

Release id:46266

The post First Hyperliquid Holders Secure Assets Against the Quantum Threat as qVAULT Launches appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Tradesman Nutrition Reviews Highlight Strong Demand for Supplements Built for Blue Collar Workers Across the United States

Published

on

San Francisco, CA, Jun 19, 2026, ZEX PR WIRE — Tradesman Nutrition is gaining growing attention across the supplement industry. Thousands of American blue-collar workers are turning to the brand for practical nutrition solutions designed around demanding physical jobs. The company is receiving a steady stream of positive customer feedback. Many reviews highlight improvements in energy, weight management, recovery, and overall daily performance.

Unlike traditional supplement brands that mainly target athletes or gym-focused consumers, Tradesman Nutrition takes a different approach. It focuses on the needs of everyday working men. The company designs its products for people working long hours in construction, electrical work, plumbing, carpentry, mechanical trades, and other physically demanding industries. These jobs require sustained energy and strong recovery.

The company explains its mission in simple terms. It aims to help working men improve fitness and energy levels. It also focuses on helping them perform at a higher standard without forcing major lifestyle changes. Customers are not asked to completely change their routines. Instead, the products are designed to fit into existing work schedules and habits.

This approach is resonating strongly with customers. Thousands of reviews across the product range reflect this response. Many users describe clear and practical benefits that relate directly to their daily work lives.

One customer, Merv A, a 60-year-old painter, shared a simple but powerful transformation. He said, “Haven’t worn my old work shirt in years, fits again now.”

Weight management and physical improvement appear often in customer feedback. Another reviewer, Shane S, a 41-year-old carpenter, reported noticeable changes while using the company’s Shred product. He said, “Been on the Shred for a few weeks and love it. Feels like it’s shredding fat while keeping me moving all day.”

Affordability and practicality are also important drivers of customer satisfaction. James C, a 21-year-old apprentice electrician, explained the financial benefit compared to his daily spending habits. He said, “As an apprentice, I was sick of paying 7 dollars a day at the servo, so happy I found something way cheaper and it works way better.”

These testimonials reflect a broader pattern across the customer base. Many tradesmen are looking for simple ways to improve health without adding complexity to their already demanding schedules. Reviewers often mention that the products fit easily into their daily routines. This includes use on job sites, during travel, and in early morning starts.

A major theme in Tradesman Nutrition Reviews is sustained energy throughout long workdays. Customers frequently report improved endurance. They also describe reduced fatigue and better focus during long shifts. For workers who start early and finish late, steady energy is important for both productivity and safety.

Weight management is another commonly reported benefit. Many customers who use Shred and related products report visible changes in body composition. They report these results while continuing physically intense labor. Unlike structured fitness programs that require gym time and strict dieting, users say the products integrate naturally into their work routines.

Recovery and rest also appear often in customer feedback. Many tradesmen report improved sleep quality and faster recovery after demanding workdays. Given the physical strain of blue-collar work, this benefit has become a key factor in customer satisfaction.

The company reports serving more than 100,000 American blue-collar workers. It also maintains a 4.9-star average rating among its customers. Thousands of reviews across multiple products continue to reinforce its market position. These products include Energy Drink, Sleep formula, Shred, T Fuel, and Creatine. The feedback supports its identity as a brand created for working men rather than general fitness consumers.

Another consistent theme in reviews is accessibility. Many customers say they had never considered supplements before discovering Tradesman Nutrition. The brand’s focused messaging has introduced nutrition support to a new audience. These are men who view nutrition as a practical tool for work performance rather than a fitness luxury.

As the company continues to expand across the United States, customer testimonials suggest strong alignment between product design and real-world needs. The focus on simplicity, affordability, and work-driven performance has helped it stand out in a crowded supplement market.

With thousands of positive reviews and growing recognition among American tradesmen, Tradesman Nutrition shows that supplements designed for physically demanding jobs can meet a long-overlooked need in the wellness industry. For many customers, the message is clear. When products are built for the realities of hard work, the results become visible in everyday life. To learn more, visit: https://tradesmannutrition.com/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST